Page 213 - Haematologica Vol. 110 - January 2025

LETTER TO THE EDITOR
References
1. Fox CP, Ahearne MJ, Pettengell R, et al. Guidelines for the management of mature T- and natural killer-cell lymphomas (excluding cutaneous T-cell lymphoma): a British Society for Haematology guideline. Br J Haematol. 2022;196(3):507-522.
2. Wang X, Zhang L, Liu X, et al. Efficacy and safety of a pegasparaginase-based chemotherapy regimen vs an L-asparaginase-based chemotherapy regimen for newly diagnosed advanced extranodal natural killer/T-cell lymphoma: a randomized clinical trial. JAMA Oncol. 2022;8(7):1035-1041.
3. Sun K-HM, Wong Y-TH, Cheung K-MC, et al. Update on molecular diagnosis in extranodal NK/T-cell lymphoma and its role in the era of personalized medicine. Diagnostics (Basel). 2022;12(2):409.
4. Huang D, Ma N, Li X, et al. Advances in single-cell RNA sequencing and its applications in cancer research. J Hematol Oncol. 2023;16(1):98.
5. Chim C-S, Ma S-Y, Au W-Y, et al. Primary nasal natural killer cell lymphoma: long-term treatment outcome and relationship with the International Prognostic Index. Blood. 2004;103(1):216-221.
6. Lee J, Suh C, Park YH, et al. Extranodal natural killer T-cell lymphoma, nasal-type: a prognostic model from a retrospective multicenter study. J Clin Oncol. 2006;24(4):612-618.
7. Kim SJ, Yoon DH, Jaccard A, et al. A prognostic index for natural killer cell lymphoma after non-anthracycline-based treatment: a multicentre, retrospective analysis. Lancet Oncol. 2016;17(3):389-400.
8. Chen S-Y, Yang Y, Qi S-N, et al. Validation of nomogram-revised
risk index and comparison with other models for extranodal nasal-type NK/T-cell lymphoma in the modern chemotherapy era: indication for prognostication and clinical decision-making. Leukemia. 2021;35(1):130-142.
9. Suzuki R, Yamaguchi M, Izutsu K, et al. Prospective measurement of Epstein-Barr virus-DNA in plasma and peripheral blood mononuclear cells of extranodal NK/T-cell lymphoma, nasal type. Blood. 2011;118(23):6018-6022.
10. Kwong Y-L, Pang AWK, Leung AYH, Chim C-S, Tse E. Quantification of circulating Epstein-Barr virus DNA in NK/T-cell lymphoma treated with the SMILE protocol: diagnostic and prognostic significance. Leukemia. 2014;28(4):865-870.
11. Pak K, Kim BS, Kim K, et al. Prognostic significance of standardized uptake value on F18-FDG PET/CT in patients with extranodal nasal type NK/T cell lymphoma: a multicenter, retrospective analysis. Am J Otolaryngol. 2018;39(1):1-5.
12. Qin C, Yang S, Sun X, Xia X, Li C, Lan X. 18F-FDG PET/CT for prognostic stratification of patients with extranodal natural killer/T-cell lymphoma. Clin Nucl Med. 2019;44(3):201-208.
13. Huang D, Li Q, Li X, et al. The novel prognostic index model of combining circulating tumor DNA and PINK-E predicts the clinical outcomes for newly diagnosed extranodal NK/T-cell lymphoma. Hemasphere. 2023;7(1):e822.
14. Li Q, Zhang W, Li J, et al. Plasma circulating tumor DNA assessment reveals KMT2D as a potential poor prognostic factor in extranodal NK/T-cell lymphoma. Biomark Res. 2020;8:27.
Haematologica | 110 January 2025
205